The More Life Company Reports Rapid Systemic Delivery of USP Testosterone in Exploratory Quicksome™ Study

More Life Company reported results from an exploratory human pharmacokinetic study involving eight participants using USP-grade testosterone formulated with its patented Quicksome sublingual delivery technology. The study found rapid systemic appearance of testosterone following Quicksome administration, providing early supportive evidence for the company’s drug-delivery platform. The limited, exploratory study size constrains the near-term commercial significance.

Analysis

This is not yet a valuation-changing clinical readout: an eight-subject pharmacokinetic exercise can establish formulation feasibility, but it does not establish therapeutic equivalence, safety across chronic use, dose reproducibility, abuse potential, or a viable regulatory path. For a micro-cap issuer, the near-term market effect is more likely promotional liquidity and financing optionality than a durable revision to revenue expectations. The key diligence gap is whether the company can disclose quantitative PK metrics—Cmax, Tmax, AUC, inter-subject variability, and comparison with approved testosterone formulations—rather than relying on qualitative rapid-absorption language.

The economic hurdle is high even if delivery works. Testosterone replacement is already served by low-cost generics, topical products, injections, pellets, and newer oral options; a premium sublingual product needs demonstrably superior onset, convenience, adherence, or safety to overcome payer resistance and commercialization spend. If Quicksome can reduce hepatic exposure versus oral testosterone while delivering consistent levels, potential strategic value lies in licensing the platform to established specialty-pharma marketers, not in a stand-alone launch by MLCO.

Over the next 1-3 months, watch for a full data release, protocol details, an FDA meeting or stated 505(b)(2) strategy, and financing terms. Absence of these items would make any price strength difficult to underwrite; over 6-18 months, the decisive catalysts are a properly powered comparative PK/safety study, manufacturability evidence, and a commercial partner. The thesis is falsified if variability is high, exposure is insufficient versus approved alternatives, or capital is raised at a deeply discounted price with dilutive warrants.

Key Decisions for Investors

• No core position in MLCO/TMLCF at this stage; treat any volume-driven move as an event watch rather than evidence of de-risked clinical or commercial value.
• Set an alert for release of numerical PK data and a defined FDA pathway. Reassess only if the company shows competitive exposure consistency and identifies a funded development plan or credible licensing partner.
• For any tactical exposure, use only highly liquid instruments and require a predefined exit around financing or regulatory disclosures; OTC/CSE liquidity, spread risk, and dilution can dominate fundamental upside.
• Monitor established testosterone-market participants and specialty-pharma acquirers for licensing signals, but do not infer read-through to larger listed peers until MLCO demonstrates differentiated PK and regulatory feasibility.